TRIZIVIR (abacavir/lamivudine/zidovudine) Patient Assistance Program
Don’t let the high cost of brand single-tablet HIV NRTI regimen disrupt your treatment. We help eligible patients access Trizivir (abacavir/lamivudine/zidovudine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Trizivir (abacavir 300 mg / lamivudine 150 mg / zidovudine 300 mg) is a fixed-dose combination of three NRTIs FDA-approved for HIV-1 infection. It is no longer first-line therapy — modern HIV guidelines recommend INSTI-based regimens (Biktarvy, Triumeq, Dovato) over older NRTI-triple regimens like Trizivir.
- Without assistance, brand Trizivir costs commonly run approximately $2,200–$2,700 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Trizivir for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- Generic abacavir/lamivudine/zidovudine is now available at substantially lower cost. HLA-B*5701 testing is required before starting. Most patients on Trizivir would benefit from switching to a modern INSTI-based regimen — discuss with your HIV provider.
What Is Trizivir Prescription Assistance Program?
The Trizivir Prescription Assistance Program is a manufacturer-sponsored initiative that provides Trizivir at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HIV patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, HIV provider coordination, HLA-B*5701 testing documentation, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, brand Trizivir costs roughly $2,200–$2,700/month. Generic alternatives are much cheaper. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$2,600 | Save ~$2,530/mo |
| CVS Pharmacy (brand) | ~$2,700 | Save ~$2,630/mo |
| Walmart (brand) | ~$2,300 | Save ~$2,230/mo |
| Costco (brand) | ~$2,250 | Save ~$2,180/mo |
Generic ABC/3TC/AZT | ~$200 | Already low |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Trizivir Prescription Program?
The Patient Assistance Program is free to apply for and provides Trizivir at no medication cost if approved. Our $69.95/month service covers full advocacy. With modern INSTI-based regimens (Biktarvy, Triumeq, Dovato) generally preferred over older NRTI-triple regimens, and generic abacavir/lamivudine/zidovudine available at much lower cost, we’ll help your provider determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Trizivir:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $2,200–$2,700 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Trizivir assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Trizivir Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Trizivir:
Trizivir is an older fixed-dose combination of three NRTIs (abacavir, lamivudine, zidovudine/AZT) for HIV-1. It was developed when NRTI-triple regimens were a viable option, but virologic potency is inferior to INSTI-based regimens. Modern HIV guidelines recommend INSTI-based regimens (Biktarvy, Triumeq, Dovato) for treatment-naïve patients. Trizivir is mostly historical now.
How Trizivir Works:
Trizivir combines three NRTI medications—abacavir, lamivudine, and zidovudine—which all work by embedding themselves into the growing viral DNA chain to halt HIV reverse transcriptase. While this triple-NRTI combination provides antiviral activity, it is less potent and carries higher long-term toxicity than modern integrase-inhibitor-based regimens. Specifically, the zidovudine component causes significant bone marrow suppression, mitochondrial toxicity, and issues like lipoatrophy and neuropathy. Because of these safety concerns and lower potency, triple-NRTI regimens fell out of favor years ago.
Form and use:
Trizivir is administered orally as a single tablet taken twice daily, and it can be used with or without food. Before a patient can begin treatment, mandatory HLA-B*5701 genetic testing is required due to the risk of severe abacavir hypersensitivity reactions. Additionally, because the medication is cleared through the kidneys, patients may require renal dose adjustments depending on their level of kidney function.
Generic availability:
Generic versions of the abacavir/lamivudine/zidovudine combination tablet are available, but far better options exist for the majority of HIV patients. Modern, once-daily single-tablet regimens like Biktarvy, Triumeq, and Dovato are preferred because they offer better safety profiles and eliminate the highly toxic zidovudine component. For patients who are currently stable on Trizivir, clinical recommendations often suggest switching to Triumeq or Biktarvy to benefit from both improved safety and a simpler once-daily dosing schedule.
Warnings:
Trizivir carries multiple severe Boxed Warnings, including fatal abacavir hypersensitivity reactions in HLA-B*5701-positive patients and severe zidovudine-induced hematologic toxicities like neutropenia and anemia, which require regular blood count monitoring. It also features Boxed Warnings for muscle wasting from prolonged zidovudine use, severe liver problems accompanied by lactic acidosis, and sudden hepatitis B flare-ups if the drug is stopped in co-infected patients. Other notable warnings include body fat redistribution, immune reconstitution syndrome, and liver decompensation in patients undergoing concurrent hepatitis C therapy with interferon-ribavirin.
FAQ (Frequently Asked Questions)
How Much Does Trizivir Cost Without Insurance?
Brand Trizivir costs approximately $2,200–$2,700 per 30-day supply. Generic abacavir/lamivudine/zidovudine is dramatically cheaper. Through AffordMyPrescriptions, qualifying patients receive Trizivir at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Should I Be On A Modern HIV Regimen Instead?
Almost certainly yes. Trizivir is an older NRTI-triple regimen with significant long-term toxicity from zidovudine (anemia, neutropenia, lipoatrophy, mitochondrial toxicity) and inferior virologic potency to modern INSTI-based regimens. If you’ve been on Trizivir for many years, discuss with your HIV provider about switching to Triumeq (uses two of the same NRTIs without zidovudine) or Biktarvy (different NRTI backbone with TAF instead of TDF/AZT). Modern regimens are once-daily, more effective, and have much better long-term safety.
Why Do I Need HLA-B*5701 Testing?
Abacavir (a Trizivir component) causes severe, sometimes fatal hypersensitivity reactions in patients carrying the HLA-B*5701 allele. HLA-B*5701 testing must be done BEFORE starting any abacavir-containing therapy (Trizivir, Triumeq, Epzicom, Ziagen). HLA-B*5701-positive patients should never receive abacavir.
What's The Zidovudine (AZT) Toxicity?
Zidovudine is the original HIV antiretroviral (approved 1987). Long-term zidovudine causes anemia and neutropenia (bone marrow suppression — requires regular CBC monitoring), lipoatrophy (loss of subcutaneous fat from face, arms, legs, buttocks — can be cosmetically distressing and partially irreversible), peripheral neuropathy, myopathy, and rare lactic acidosis from mitochondrial toxicity. These toxicities are why zidovudine-containing regimens are no longer first-line.
Can I Get Trizivir Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify. However, with generic alternatives much cheaper, many Medicare patients access affordable HIV therapy without PAP.
What If I Have Hepatitis B Co-infection?
Lamivudine has HBV activity but is not adequate alone (HBV resistance develops). HIV/HBV co-infected patients typically need a tenofovir-containing regimen. Discuss with your HIV provider — switching from Trizivir to a tenofovir-based regimen may be appropriate.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic abacavir/lamivudine/zidovudine (much cheaper), or to a modern single-tablet regimen like Triumeq or Biktarvy (each with its own PAP), state ADAP, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Trizivir, our team may be able to help you access assistance programs — or guide you to a modern, safer single-tablet HIV regimen. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.